1 Min Read
Dec 13 (Reuters) - Proteon Therapeutics Inc said its experimental chronic kidney disease drug failed to meet the main goal in a late-stage study.
The drug, vonapanitase, was being tested against a placebo in certain patients on or expecting to undergo dialysis.
The company's shares were halted in premarket trading. (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva)